Etoposide is available as an oral or IV preparation chemotherapy agent.

Common dosing regimens for approved indications include:

- For refractory testicular cancer

- 50 to 100 mg/m^2 per daily single dose on days 1 through 5 of a 21-day cycle. Alternately, dosing can be 100 mg/m^2 daily on days 1, 3, and 5 of a 21-day cycle.

- For small cell lung cancer:

- Oral dosing: 70 mg/m^2 orally each day for the first 4 days, up to 100 mg/m^2 orally for the first 5 days of a 21 or 28-day cycle.
- IV dosing: 35 mg/m^2 IV for the first 4 days, up to 50 mg/m^2 for the first 5 days of a 21 or 28-day cycle.

Renal dosing adjustments: for CrCl of 15 to 50, decrease the typical dose 25%, CrCl under 15 cut dose by 50%. For peritoneal or hemodialysis patients, cut the dose by 50%.

As part of the bleomycin, etoposide, cisplatin (BEP) therapy, etoposide has been proven effective for metastatic non-seminomatous testicular cancer and malignant ovarian germ cell tumors.